These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7904641)

  • 1. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.
    Shah VP; Midha KK; Dighe S; McGilveray IJ; Skelly JP; Yacobi A; Layloff T; Viswanathan CT; Cook CE; McDowall RD
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):249-55. PubMed ID: 1823867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence.
    Chen ML; Blume H; Beuerle G; Mehta M; Potthast H; Brandt A; Schug BS; Ducharme M; Endrenyi L; Gallicano K; Schuirmann D; Welink J
    Eur J Pharm Sci; 2019 Jan; 127():24-28. PubMed ID: 30342171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
    Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
    Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The global bioequivalence harmonisation initiative: Report of EUFEPS/AAPS third conference.
    Mehta M; Blume H; Beuerle G; Tampal N; Schug B; Potthast H; Jiang W; Wilson C
    Eur J Pharm Sci; 2020 Aug; 151():105383. PubMed ID: 32473200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis.
    Savoie N; Booth BP; Bradley T; Garofolo F; Hughes NC; Hussain S; King SP; Lindsay M; Lowes S; Ormsby E; Phull R; Rocci ML; Vallano PT; Viau A; Zhu Z
    Bioanalysis; 2009 Apr; 1(1):19-30. PubMed ID: 21083184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIO-international '94 Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies and Pre-Conference Satellite on 'In Vivo/In Vitro Correlation'. Munich, Germany, June 14-17, 1994.
    Blume HH; McGilveray IJ; Midha KK
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):3-13. PubMed ID: 7588991
    [No Abstract]   [Full Text] [Related]  

  • 9. Conference report: Bio-International 2005.
    Midha KK; Shah VP; Singh GJ; Patnaik R
    J Pharm Sci; 2007 Apr; 96(4):747-54. PubMed ID: 17094144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolites and bioequivalence: past and present.
    Jackson AJ; Robbie G; Marroum P
    Clin Pharmacokinet; 2004; 43(10):655-72. PubMed ID: 15244496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When are bioavailability studies required? A German proposal.
    Gleiter CH; Klotz U; Kuhlmann J; Blume H; Stanislaus F; Harder S; Paulus H; Poethko-Müller C; Holz-Slomczyk M
    J Clin Pharmacol; 1998 Oct; 38(10):904-11. PubMed ID: 9807970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and bioequivalence.
    Skelly JP
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):539-45. PubMed ID: 977792
    [No Abstract]   [Full Text] [Related]  

  • 13. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and bioequivalence: focus on physiological factors and variability.
    Karalis V; Macheras P; Van Peer A; Shah VP
    Pharm Res; 2008 Aug; 25(8):1956-62. PubMed ID: 18551249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.
    Hughes JH; Upton RN; Foster DJR
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):233-244. PubMed ID: 28194623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs.
    Hammami MM; Yusuf A; Shire FS; Hussein R; Al-Swayeh R
    J Negat Results Biomed; 2017 May; 16(1):10. PubMed ID: 28535819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.